Trial
NCT05895552
A Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Reata, a wholly owned subsidiary of Biogen
Collaborators
—
Condition
Diabetic Peripheral Neuropathic Pain
Intervention
RTA 901
Why stopped
Sponsor decision to close study early; not due to safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-15